Dana-Farber Cancer Institute | Strategic Alliance Partners

April 23, 2019

Paul G. Richardson, MD, clinical program leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine, Harvard Medical School, discusses treatment approaches targeting mutational burden in multiple myeloma.

April 22, 2019

Omar Nadeem, MD, highlights exciting approaches that have emerged in relapsed/refractory myeloma, such as CAR T-cell therapy, and shares unanswered questions that future research should address.

April 22, 2019

Ann S. LaCasce, MD, MMSc, director of Dana-Farber/Partners CancerCare Hematology-Medical Oncology Fellowship Program, institute physician, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, discusses the future of mantle cell lymphoma treatment.

April 22, 2019

Paul G. Richardson, MD, highlights the many promising agents that have emerged in relapsed/refractory multiple myeloma in recent years, remaining challenges, and hope for continued progress.

April 19, 2019

Matthew S. Davids, MD, MMSc, discusses recent shifts in the chronic lymphocytic leukemia paradigm with the use of novel therapies and the need to increase personalized treatment with these agents.

April 19, 2019

Giada Bianchi, MD, discusses the scope of frontline therapy and subsequent maintenance strategies among patients with transplant eligible and ineligible newly diagnosed multiple myeloma.

April 19, 2019

Christine N. Duncan, MD, senior physician, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the use of CAR T-cell therapy in the treatment of pediatric patients with acute lymphocytic leukemia (ALL).

April 18, 2019

Ann S. LaCasce, MD, MMSc, director of Dana-Farber/Partners CancerCare Hematology-Medical Oncology Fellowship Program, institute physician, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, discusses key advances made in the mantle cell lymphoma (MCL) paradigm.

April 17, 2019

Ann S. LaCasce, MD, MMSc, highlights the therapeutic progress in the treatment of patients with mantle cell lymphoma , key remaining challenges, and where future research is headed.

April 16, 2019

Joyce F. Liu, MD, MPH, assistant professor of medicine, Harvard Medical School, and director of clinical research for gynecologic oncology at Dana-Farber Cancer Institute, discusses the use of PARP inhibitors in patients with recurrent ovarian cancer.

April 11, 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses atezolizumab plus bevacizumab in patients with non–clear cell renal cell carcinoma.

April 04, 2019

Suzanne George, MD, director of Clinical Research, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, and an associate professor of medicine, Harvard Medical School, discusses the importance of collaboration in the treatment of patients with uterine sarcoma.

March 29, 2019

Although TMB is associated with responses to checkpoint inhibitor therapy, more research is needed to better understand how TMB interacts with other genomic correlates of the immune cycle before the biomarker can be incorporated into clinical practice.

March 26, 2019

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses individualized dosing of niraparib in the treatment of patients with ovarian cancer.

March 21, 2019

Matthew S. Davids, MD, MMSc, associate director, CLL Center, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses challenges in the frontline treatment of patients with chronic lymphocytic leukemia.

March 11, 2019

Matthew S. Davids, MD, MMSc, discusses methods for choosing between frontline therapies for patients with newly diagnosed chronic lymphocytic leukemia and highlights anticipated research in the field.

March 09, 2019

Matthew S. Davids, MD, MMSc, associate director, CLL Center, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses frontline treatment approaches for patients with chronic lymphocytic leukemia.

March 08, 2019

Panagiotis A. Konstantinopoulos, MD, PhD, director of Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the role of immunotherapy in the treatment of patients with ovarian cancer.

March 08, 2019

Richard M. Stone, MD, discusses the therapeutic landscape for elderly patients with acute myeloid leukemia.

March 05, 2019

Susana Campos, MD, MPH, assistant professor of medicine, Harvard Medical School, and Dana-Farber Cancer Institute, discusses differences between PARP inhibitors in recurrent ovarian cancer.